Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab Withdrawal in Atypical Haemolytic Uraemic Syndrome (aHUS)
2017-003916-37Phase 2Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Thrombotic microangiopathy-related serious adverse events after eculizumab withdrawal. Status: unknown.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2017-003916-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003916-37.